Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-11-27
2007-11-27
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254090, C514S254030, C514S254100, C544S359000, C544S392000, C544S393000
Reexamination Certificate
active
10326365
ABSTRACT:
There is provided a series of novel α-(N-sulfonamido)acetamide compounds of the Formula (I)wherein R, R1, R2and R3are defined herein, which are inhibitors of β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid activity.
REFERENCES:
patent: 5274094 (1993-12-01), Whittaker et al.
patent: 5516783 (1996-05-01), Whittaker et al.
patent: 6153612 (2000-11-01), Ortwine et al.
patent: 11343279 (1999-12-01), None
patent: WO 00/50391 (2000-08-01), None
Golde, T.E., “Alzheimer disease therapy: Can the amyloid cascade be halted?”, J. Clin. Invest., 111:11-18 (2003).
Golde, T.E., “Alzheimer disease therapy . . . ”, J. CLin. Invest. 111:11-18 (2003). doi: 10.1172/JCI200317527.
Chapman, P. F., et al., “Imparied synaptic plasticity and learning in aged amyloid precursor protein transgenic mice”,Nature Neurosci, 2 (3), pp. 271-276 (1999).
Dahlgren, K. N., et al., “Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability”,J. Biol. Chem., 277 (35), pp. 32046-32053 (2002).
Gotz, J. et al., “Formation of Neurofibrillary Tangles in P301 Tau Transgenic Mice Induced by αβ42 Fibrils”,Science, 293, pp. 1491-1495 (2001).
Lewis, J., et al. “Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP”,Science, 293, pp. 1487-1491 (2001).
McLean, C. A., et al., “Soluble Pool of αβ Amyloid as a Determinant of Severity of Neurodegeneration in Alzheimer's Disease”,Ann. Neurol., 46 (6), pp. 860-866 (1999).
Seiffert, D.; et al., “Presenilin-1 and -2 are Molecular Targets for γ-Secretase Inhibitors”,J. Biol. Chem., 275 (44), pp. 34086-34091 (2000).
Selkoe, D.J., “Cell Biology of the Amyloid—β-Protein Precursor and the Mecanism of Alzheimer's Disease”,Ann. Rev. Cell Biol., 10, pp. 373-403 (1994).
Selkoe, D.J., “Alzheimer's Disease: Genes, Proteins, and Therapy”,Physiol Rev., 81, pp. 741-766 (2001).
Thal, D.R., et al. “Two Types of Sporadic Cerebral Amyloid Angiopathy”,J. Neuropath. Exp. Neuro. 61 (3), pp. 282-293 (2002).
Walsh, D. M., et al. “Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo”,Nature, 416, pp. 535-539 (2002).
Wolfe, M. J, “Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential”,J. Med. Chem., 44 (13), pp. 2039-2060 (2001).
Bergstrom Carl P.
Bronson Joanne J.
Gai Yonghua
Macor John E.
Marcin Lawrence R.
Algieri Aldo A.
Bristol--Myers Squibb Company
Ward Paul V.
Wilson James O.
LandOfFree
α-(N-sulfonamido)acetamide derivatives as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with α-(N-sulfonamido)acetamide derivatives as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and α-(N-sulfonamido)acetamide derivatives as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3848227